{"id":19159,"date":"2022-04-13T07:40:32","date_gmt":"2022-04-13T14:40:32","guid":{"rendered":"https:\/\/marketdepth.com\/?p=19159"},"modified":"2022-04-13T07:40:33","modified_gmt":"2022-04-13T14:40:33","slug":"glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology","status":"publish","type":"post","link":"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/","title":{"rendered":"GlaxoSmithKline plc Strikes Deal to Acquire Sierra Oncology"},"content":{"rendered":"\n

Sierra Oncology, Inc (Nasdaq: SRRA)<\/strong> surged over 37% in premarket trading after GlaxoSmithKline plc (GSK) agreed <\/a>to acquire the former for $1.9 billion.<\/p>\n\n\n\n

Cash per Share<\/h5>\n\n\n\n

GSK will pay $55 per share of common stock in cash representing an approximate total equity value of $1.9 billion for the California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer. Sierra Oncology\u2019s differentiated momelotinib has the potential to address the critical unmet medical needs of myelofibrosis patients with anaemia, and the proposed acquisition would see momelotinib complements GSK\u2019s existing expertise in haematology.\u00a0<\/p>\n\n\n\n

“Sierra Oncology complements our commercial and medical expertise in haematology. Momelotinib offers a differentiated treatment option that could address the significant unmet medical needs of myelofibrosis patients with anaemia, the major reason patients discontinue treatment. With this proposed acquisition, we have the opportunity to potentially bring meaningful new benefits to patients and further strengthen our portfolio of specialty medicines.\u201d<\/p>Luke Miels, Chief Commercial Officer, GSK<\/cite><\/blockquote>\n\n\n\n

The acquisition will be effected through a one-step merger in which the shares of Sierra Oncology outstanding will be canceled and converted into the right to receive $55 per share in cash, representing a premium of approximately 39% to Sierra Oncology\u2019s closing stock price on April 12th, 2022.<\/p>\n\n\n\n

“Uniting with GSK creates the best opportunity for Sierra Oncology to realise its mission of delivering targeted therapies that treat rare forms of cancer while also delivering compelling and certain value for our stockholders. Now we have a partner with a global infrastructure and oncology expertise that enables us to deliver momelotinib to patients as quickly as possible and on a global scale.”<\/p>Stephen Dilly, MBBS, PhD, President and Chief Executive Officer, Sierra Oncology<\/cite><\/blockquote>\n","protected":false},"excerpt":{"rendered":"Sierra Oncology, Inc (Nasdaq: SRRA) surged over 37% in premarket trading after GlaxoSmithKline plc (GSK) agreed to acquire the former for $1.9 billion. Cash per Share GSK will pay $55 per share of common stock in cash representing an approximate total equity value of $1.9 billion for the California-based, late-stage biopharmaceutical company focused on targeted… View Article<\/a>","protected":false},"author":3,"featured_media":18983,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":0,"footnotes":""},"categories":[9,17,8,11,16],"tags":[],"acf":[],"yoast_head":"\nGlaxoSmithKline plc Strikes Deal to Acquire Sierra Oncology - MarketDepth<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GlaxoSmithKline plc Strikes Deal to Acquire Sierra Oncology - MarketDepth\" \/>\n<meta property=\"og:description\" content=\"Sierra Oncology, Inc (Nasdaq: SRRA) surged over 37% in premarket trading after GlaxoSmithKline plc (GSK) agreed to acquire the former for $1.9 billion. Cash per Share GSK will pay $55 per share of common stock in cash representing an approximate total equity value of $1.9 billion for the California-based, late-stage biopharmaceutical company focused on targeted... View Article\" \/>\n<meta property=\"og:url\" content=\"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"MarketDepth\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/marketdepthnews\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-13T14:40:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-13T14:40:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/marketdepth.com\/wp-content\/uploads\/2022\/03\/Covid19Molecule.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"MarketDepth\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MarketDepthNews\" \/>\n<meta name=\"twitter:site\" content=\"@MarketDepthNews\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"MarketDepth\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/\"},\"author\":{\"name\":\"MarketDepth\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69\"},\"headline\":\"GlaxoSmithKline plc Strikes Deal to Acquire Sierra Oncology\",\"datePublished\":\"2022-04-13T14:40:32+00:00\",\"dateModified\":\"2022-04-13T14:40:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/\"},\"wordCount\":287,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/marketdepth.com\/#organization\"},\"articleSection\":[\"Biotechnology\",\"Headlines\",\"Healthcare\",\"Investing\",\"What's Hot\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/\",\"url\":\"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/\",\"name\":\"GlaxoSmithKline plc Strikes Deal to Acquire Sierra Oncology - MarketDepth\",\"isPartOf\":{\"@id\":\"https:\/\/marketdepth.com\/#website\"},\"datePublished\":\"2022-04-13T14:40:32+00:00\",\"dateModified\":\"2022-04-13T14:40:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/marketdepth.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GlaxoSmithKline plc Strikes Deal to Acquire Sierra Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/marketdepth.com\/#website\",\"url\":\"https:\/\/marketdepth.com\/\",\"name\":\"MarketDepth\",\"description\":\"Stock Market News & Headlines\",\"publisher\":{\"@id\":\"https:\/\/marketdepth.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/marketdepth.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/marketdepth.com\/#organization\",\"name\":\"MarketDepth\",\"url\":\"https:\/\/marketdepth.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg\",\"contentUrl\":\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg\",\"width\":1500,\"height\":1000,\"caption\":\"MarketDepth\"},\"image\":{\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/marketdepthnews\",\"https:\/\/twitter.com\/MarketDepthNews\",\"https:\/\/www.instagram.com\/marketdepth\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69\",\"name\":\"MarketDepth\",\"url\":\"https:\/\/marketdepth.com\/author\/3\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GlaxoSmithKline plc Strikes Deal to Acquire Sierra Oncology - MarketDepth","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/","og_locale":"en_US","og_type":"article","og_title":"GlaxoSmithKline plc Strikes Deal to Acquire Sierra Oncology - MarketDepth","og_description":"Sierra Oncology, Inc (Nasdaq: SRRA) surged over 37% in premarket trading after GlaxoSmithKline plc (GSK) agreed to acquire the former for $1.9 billion. Cash per Share GSK will pay $55 per share of common stock in cash representing an approximate total equity value of $1.9 billion for the California-based, late-stage biopharmaceutical company focused on targeted... View Article","og_url":"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/","og_site_name":"MarketDepth","article_publisher":"https:\/\/www.facebook.com\/marketdepthnews","article_published_time":"2022-04-13T14:40:32+00:00","article_modified_time":"2022-04-13T14:40:33+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/marketdepth.com\/wp-content\/uploads\/2022\/03\/Covid19Molecule.jpg","type":"image\/jpeg"}],"author":"MarketDepth","twitter_card":"summary_large_image","twitter_creator":"@MarketDepthNews","twitter_site":"@MarketDepthNews","twitter_misc":{"Written by":"MarketDepth","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/#article","isPartOf":{"@id":"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/"},"author":{"name":"MarketDepth","@id":"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69"},"headline":"GlaxoSmithKline plc Strikes Deal to Acquire Sierra Oncology","datePublished":"2022-04-13T14:40:32+00:00","dateModified":"2022-04-13T14:40:33+00:00","mainEntityOfPage":{"@id":"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/"},"wordCount":287,"commentCount":0,"publisher":{"@id":"https:\/\/marketdepth.com\/#organization"},"articleSection":["Biotechnology","Headlines","Healthcare","Investing","What's Hot"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/","url":"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/","name":"GlaxoSmithKline plc Strikes Deal to Acquire Sierra Oncology - MarketDepth","isPartOf":{"@id":"https:\/\/marketdepth.com\/#website"},"datePublished":"2022-04-13T14:40:32+00:00","dateModified":"2022-04-13T14:40:33+00:00","breadcrumb":{"@id":"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/marketdepth.com\/glaxosmithkline-plc-strikes-deal-to-acquire-sierra-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/marketdepth.com\/"},{"@type":"ListItem","position":2,"name":"GlaxoSmithKline plc Strikes Deal to Acquire Sierra Oncology"}]},{"@type":"WebSite","@id":"https:\/\/marketdepth.com\/#website","url":"https:\/\/marketdepth.com\/","name":"MarketDepth","description":"Stock Market News & Headlines","publisher":{"@id":"https:\/\/marketdepth.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/marketdepth.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/marketdepth.com\/#organization","name":"MarketDepth","url":"https:\/\/marketdepth.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/","url":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg","contentUrl":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg","width":1500,"height":1000,"caption":"MarketDepth"},"image":{"@id":"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/marketdepthnews","https:\/\/twitter.com\/MarketDepthNews","https:\/\/www.instagram.com\/marketdepth\/"]},{"@type":"Person","@id":"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69","name":"MarketDepth","url":"https:\/\/marketdepth.com\/author\/3\/"}]}},"_links":{"self":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/19159"}],"collection":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/comments?post=19159"}],"version-history":[{"count":1,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/19159\/revisions"}],"predecessor-version":[{"id":19160,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/19159\/revisions\/19160"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/media\/18983"}],"wp:attachment":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/media?parent=19159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/categories?post=19159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/tags?post=19159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}